Organization Profile

You just read:

Bristol-Myers Squibb's immunotherapy Opdivo™ (nivolumab) approved by Health Canada for the treatment of previously untreated BRAF V600 wild-type metastatic melanoma

News provided by

Bristol-Myers Squibb Canada

Sep 25, 2015, 17:05 ET